Drug Trial Radar · NCT05506943
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
168
Actual
Start
Jan 9, 2023
Primary completion
Aug 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Compass TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
Conditions
- Biliary Tract Cancer
- Cholangiocarcinoma
- Gall Bladder Cancer
- Ampullary Cancer
Interventions
CTX-009Drug
IV infusion on day 1 and 14 of every 28 day cycle
PaclitaxelDrug
IV infusion on day 1, 8, and 15 of every 28 day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Overall ResponseTime frame: From randomization to treatment discontinuation for any reason, average 6 months
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
University of Arizona
Tucson, Arizona
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California
Stanford Medicine Cancer Center
Palo Alto, California
University of California San Francisco
San Francisco, California
Rocky Mountain Cancer Centers, LLP
Aurora, Colorado
University of Florida
Gainesville, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida
AdventHealth Orlando
Orlando, Florida
Northwestern University
Chicago, Illinois
University of Chicago
Chicago, Illinois
Ochsner Clinic Foundation
New Orleans, Louisiana
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Mayo Clinic Rochester
Rochester, Minnesota
Washington University School of Medicine, Siteman Cancer Center
St Louis, Missouri
Rutgers Cancer Institute
New Brunswick, New Jersey
The University of New Mexico
Albuquerque, New Mexico
Memorial Medical Center
Las Cruces, New Mexico
Roswell Park
Buffalo, New York
Columbia University
New York, New York
Montefiore Medical Center
The Bronx, New York
Gabrail Cancer Center
Canton, Ohio
Cleveland Clinic
Cleveland, Ohio
University of Tennessee Medical Center
Knoxville, Tennessee
SCRI Oncology Partners
Nashville, Tennessee
Texas Oncology - Austin
Austin, Texas
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Texas Oncology - Dension
Denison, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Texas Oncology - San Antonio
San Antonio, Texas
Texas Oncology - Northeast Texas
Tyler, Texas
Virginia Mason Franciscan Health
Seattle, Washington
Northwest Cancer Specialists, P.C.
Vancouver, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.